Caris Life Sciences to Present Seven Precision Oncology Studies at IASLC 2026 World Conference on Lung Cancer
核心洞察
Caris Life Sciences will present seven studies at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea, from September 12–15, 2026, spanning two mini oral presentations, one Poster Tour, and four posters.
A 39,124-sample NSCLC analysis found PRMT5-high/MTAP (搜索)-deleted tumors had the shortest overall survival and fewer CD8+ T-cells, suggesting a less favorable immune microenvironment.
A 43,261-sample study identified race- and ethnicity-associated differences in tumor genomics and immunotherapy outcomes, with non-Hispanic Black patients achieving longer survival despite more resistance alterations.
Caris Life Sciences (NASDAQ: CAI), a leading TechBio company, announced that researchers from Caris and the Caris Precision Oncology Alliance (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12–15, 2026, in Seoul, South Korea. The research program includes two mini oral presentations, one Poster Tour presentation, and four poster presentations, all highlighting how comprehensive molecular profiling and AI-driven clinico-genomic analyses are advancing understanding of lung cancer biology, immunotherapy response, and precision treatment strategies.
"This year's presentations underscore the power of large-scale molecular and clinico-genomic datasets in revealing meaningful insights into cancer biology and therapeutic response," said George W. Sledge, Jr., M.D., Chief Medical Officer of Caris Life Sciences. "From immunotherapy biomarkers and tumor microenvironment analyses to germline testing and targeted therapy outcomes, these findings demonstrate how comprehensive molecular profiling can help inform clinical decision-making and accelerate the future of precision oncology."
PRMT5 Expression and MTAP Deletion in NSCLC
One mini oral presentation evaluated the impact of Protein Arginine Methyltransferase 5 (PRMT5) expression and MTAP (搜索) deletion on overall survival and immune cells in non-small cell lung cancer (搜索) (NSCLC). Analysis of 39,124 NSCLC samples found that MTAP-deleted tumors demonstrated higher PRMT5 expression. PRMT5-high/MTAP-deleted tumors were associated with the shortest overall survival across molecular subtypes. Among patients treated with immune checkpoint inhibitors, PRMT5-high/MTAP-deleted tumors were associated with shorter overall survival than PRMT5-high/MTAP-non-deleted tumors. Furthermore, PRMT5-high/MTAP-deleted tumors exhibited fewer CD8+ T-cells and other adaptive immune cells, suggesting a less favorable immune microenvironment.
Immunotherapy Biomarkers and Outcomes by Race/Ethnicity
A second mini oral presentation examined the prevalence of immunotherapy (IO) biomarkers, tumor microenvironment (TME) composition, and survival by race/ethnicity in NSCLC. Evaluation of 43,261 NSCLC samples identified race- and ethnicity-associated differences in tumor genomics, immune microenvironment composition, and clinical outcomes. Non-Hispanic Asian Pacific Islander patients demonstrated longer overall survival and fewer genomic alterations associated with resistance to immunotherapy than non-Hispanic White patients. Notably, among immunotherapy-treated patients, non-Hispanic Black patients achieved longer survival despite a higher prevalence of immunotherapy-resistance molecular alterations.
Transcriptomic Subtypes in Mesothelioma
A Poster Tour presentation examined transcriptomic subtypes predicting frontline therapy response in pleural (MPM) and peritoneal mesothelioma (搜索) (MPeM). Transcriptomic analysis of 386 mesothelioma samples identified three biologically distinct clusters with unique molecular features and treatment outcomes. Chemotherapy, with or without bevacizumab, was associated with longer overall survival than immune checkpoint inhibitor therapy in two of the three clusters. If validated prospectively, the identified transcriptomic subtypes could help inform therapeutic decision-making and support a more personalized treatment approach for mesothelioma.
Germline Variant Analyses
Two poster presentations characterized germline alterations across lung cancer subtypes. In NSCLC, clinically relevant germline alterations were identified in 12.2% of 3,609 patients, with frequently altered genes including MUTYH, CHEK2, ATM, BRCA2, and MITF. Among patients with linked tumor profiling, 45.8% of pathogenic, likely pathogenic, or risk germline variants had a matching tumor variant. In small cell lung cancer (搜索), clinically relevant germline alterations were identified in 13.4% of 149 patients with germline findings, with common alterations including MUTYH, APC, ATM, BRIP1, and CHEK2. In patients with linked tumor sequencing, more than half of pathogenic, likely pathogenic, or risk germline variants had corresponding tumor variants.
RET-Positive Lung Cancer and ITGB6 Expression
An additional poster examined clinico-biological characteristics and treatment outcomes in patients with RET (搜索)-positive lung cancer with non-lung adenocarcinoma (LUAD) histology. Among 588 RET-positive patients in the RET-MAP registry, 45 patients (7.7%) had non-LUAD histology. Non-LUAD histology was independently associated with shorter progression-free and overall survival following both selective RET inhibitors and first-line chemotherapy. Patients with large cell neuroendocrine carcinoma demonstrated a 75% objective response rate to selective RET inhibitors, with survival outcomes comparable to LUAD.
A final poster evaluated ITGB6 (搜索) expression and real-world outcomes in NSCLC. Analysis of 34,022 NSCLC samples demonstrated that ITGB6 expression varies by histology and genomic context. High ITGB6 expression was associated with improved overall survival in lung adenocarcinoma but poorer outcomes in lung squamous cell carcinoma. These opposing prognostic associations support further evaluation of ITGB6 across molecularly defined NSCLC populations.
Research highlights will be available at Caris' booth #813, with full abstracts available on the Caris website.